Zusammenfassung
Antimykotika werden entsprechend der Bedeutung von Pilzinfektionen der Haut und Schleimhäute zu etwa 90% als Lokaltherapeutika eingesetzt. Insge-samt nimmt die Verordnung seit 1996 kontinuierlich ab. Lediglich die topischen Antimykotikakombinationen haben 2003 erstmals wieder deutlich zugenom-men.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Abeck D, Gruseck E, Korting HC, Ring J (1996): Onychomykose: Epidemiologic, Pathogenese, Klinik, Mikrobiologie und Therapie. Dtsch Ärztebl 93: A-2027–2032.
Akpan A, Morgan R (2002): Oral candidiasis. Postgrad Med J 78:455–459.
Albougy HA, Naidoo S (2002): A systematic review of the management of oral candidiasis associated with HIV/AIDS. J South African Dent Ass 57: 457–466.
Alston SJ, Cohen BA, Braun M (2003): Persistent and recurrent tinea corporis in children treated with combination antifungal/corticosteroid agents. Pediatrics 111:201–203.
Amichai B, Grunwald MH (1998): Adverse drug reactions of the new oral antifungal agents — terbinafine, fluconazole, and itraconazole. Int J Dermatol 37:410–415.
Area E, Tastan HB, Akar A, Kurumlu Z, Gur AR (2002): An open, randomized, comparative study of oral fluconazole, itraconazole and terbinafine therapy in onychomycosis. J Dermatol Treat 13: 3–9.
Bell-Syer SEM, Hart R, Crawford F, Torgerson DJ, Tyrell W, Russell I (2003): Oral treatments for fungal infections of the skin of the foot (Cochrane Review). In: The Cochrane Library, Issue 2 2003. Oxford: Update Software.
Bennett ML, Fleischer AB, Loveless JW, Feldman SR (2000): Oral griseofulvin remains the treatment of choice for tinea capitis in children. Ped Dermatol 17: 304–309.
Blaschke-Hellmessen R, Buchmann H, Schwarze R (1996): Einfluß oral verabreich-ter Polyenantibiotika auf die Hefepilzbesiedlung des Darmtraktes: Möglich-keiten und Grenzen. Mycoses 39(Suppl 1): 33–39.
Bodman MA, Feder L, Nace AM (2003): Topical treatments for onychomycosis. A historical perspective. J Am Podiatr Med Ass 93:136–141.
Casciano J, Amaya K, Doyle J, Arikian S, Shear N, Haspel M, Kahler K (2003): Economic analysis of oral and topical therapies for onychomycosis of the toenails and fingernails. Manag Care 12: 47–54.
Chan YC, Friedlander SF (2004): New treatments for tinea capitis. Curr Opin Infect Dis 17: 97–103.
Crawford F, Young P, Godfrey C, Bell-Syer SEM, Hart R, Brunt E, Russel I (2002): Oral treatments for toenail onychomycosis. Arch Dermatol 138:811–816.
Crawford F, Hart R, Bell-Syer S, Torgerson D, Young P, Russell I (2003): Topical treatments for fungal infections of the skin and nails of the foot (Cochrane Review). In: The Cochrane Library, Issue 2, 2003. Oxford: Update Software.
Darkes MJM, Scott LJ, Goa KL (2003): Terbinafine. A review of its use in onychomycosis in adults. Am J Clin Dermatol 4:39–65.
Deutsche Dermatologische Gesellschaft und Deutschsprachige Mykologische Gesell-schaft (2000): LeitlinieTinea der freien Haut. http://www.uni-duesseldorf.de/WWW/AWMF/ll/derm-m01.htm.
Deutsche Dermatologische Gesellschaft und Deutschsprachige Mykologische Gesellschaft (2002): Leitlinie Onychomykose. http://www.uni-duesseldorf.de/WWW/AWMF/ll/derm-m02. htm.
Devaraj A, O’Beirne JP, Veasey R, Dunk A (2002): Interaction between warfarin and topical miconazole cream. Br Med J 325: 77.
Dinnendahl V, Fricke U (Hrsg) (2004): Arzneistoff-Profile. Basisinformation über arzneiliche Wirkstoffe. Stammlieferung 1982 mit 1. bis 19. Ergänzungslieferung 2004, Govi-Verlag, Eschborn.
Ellis D (2002): Amphotericin B: spectrum and resistance. J Antimicrob Chemother 49(Suppl S1):7–10.
Evans EGV, Sigurgeirsson B for the LION study group (1999): Double blind, randomised study of continuous terbinafine compared with intermittent itraconazole in treatment of toenail onychomycosis. Brit Med J 318:1031–1035.
Goa KL, Barradell LB (1995): Fluconazole. An update of its pharmacodynamic and pharmacokinetic properties and therapeutic use in major superficial and systemic mycoses in immunocompromised patients. Drugs 50: 658–690.
Grant SM, Clissold SP (1989): Itraconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses. Drugs 37: 310–344.
Grant SM, Clissold SP (1990): Fluconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses. Drugs 39: 877–916.
Grotzsche PC, Johansen HK (2003): Nystatin prophylaxis and treatment in severely immunodepresses patients (Cochrane Review): In: The Cochrane Library, Issue 2 2003. Oxford: Update Software.
Gupta AK (2002): Treatment of dermatophyte toenail onychomycosis in the United States. A pharmacoeconomic analysis. J Am Pediatr Med Assoc 92: 272–286.
Gupta AK, Einarson TR, Summerbell RC, Shear NH (1998): An overview of topical antifungal therapy in dermatomycoses. A North American perspective. Drugs 55: 645–674.
Gupta AK, Shear NH (1999): The new oral antifungal agents for onychomycosis of the toenails. J Eur Acad Dermatol Venereol 13:1–13.
Gupta AK, Lynde CW, Konnikov N (2001): Single-blind, randomized, prospective study of sequential itraconazole and terbinafine pulse compared with terbinafine pulse for the treatment of toenail onychomycosis. J Am Acad Dermatol 44: 485–491.
Haria M, Bryson HM (1995): Amorolfine. A review of its pharmacological properties and therapeutic potential in the treatment of onychomycosis and other superficial fungal infections. Drugs 49:103–120.
Haria M, Bryson HM, Goa KL (1996): Itraconazole. A reappraisal of its pharmacological properties and therapeutic use in the management of superficial fungal infections. Drugs 51:585–620.
Haugh M, Helou S, Boissel JP, Cribier BJ (2002): Terbinafine in fungal infections of the nails: a meta-analysis of randomized clinical trials. Br J Dermatol 147: 118–121.
Higgins EM, Fuller LC, Smith CH (2000): Guidelines for the management of tinea capitis. Br J Dermatol 143: 53–58.
Hornstein OP, Nürnberg E (Hrsg) (1985): Externe Therapie von Hautkrankheiten: Pharmazeutische und medizinische Praxis. Georg Thieme Verlag, Stuttgart, New York, pp. 304–315.
Lacour M, Zunder T, Huber R, Sander A, Daschner F, Frank U (2002): The pathogenic significance of intestinal Candida colonization — A systematic review from an interdisciplinary and environmental medical point of view. Int J Hyg Environ Health 205: 257–268.
Male O (1981): Medizinische Mykologie fur die Praxis. Georg Thieme Verlag, Stuttgart, New York.
McClellan KJ, Wiseman LR, Markham A (1999): Terbinafine. An update of its use in superficial mycoses. Drugs 58:179–202.
Merk HF (1993): Antimykotika. Teil I und II. Hautarzt 44: 191–199 und 257–267.
Niewerth M, Korting HC (1999): Management of onychomycoses. Drugs 58:283–296.
Niewerth M, Korting HC (2000): The use of systemic antimycotics in dermato-therapy. Eur J Dermatol 10:155–160.
Patton LL, Bonito AJ, Shugars DA (2001): A systematic review of the effectiveness of antifungal drugs for the prevention and treatment of oropharyngeal candidiasis in HIV-positive patients. Oral Surg Oral Med Pathol Oral Radiol Endod 92: 170–179.
Pierard GE, Arrese JE, Pierard-Franchimont C (1996): Treatment and prophylaxis of tinea infections. Drugs 52: 209–224.
Powderly WG, Mayer KH, Perfect JR (1999): Diagnosis and treatment of oropharyngeal candidiasis in patients infected with HIV: a critical reassessment. AIDS Res Hum Retroviruses 15:1405–1412.
Quintanar-Guerrero D, Ganem-Quintanar A, Tapia-Olguin P, Kaliar YN, Buri P (1998): The effect of keratolytic agents on the permeability of three imidazole antimycotic drugs through the human nail. Drug Dev Ind Pharm 24: 685–690.
Rigopoulos D, Katoulis AC, Ioannides D, Georgala S, Kalogeromitros D, Bolbasis I et al (2003): A randomized trial of amorolfine 5% solution nail lacquer in association with itraconazole pulse therapy compared with itraconazole alone in the treatment of Candida fingernail onychomycosis. Br J Dermatol 149:151–156.
Ring J, Fröhlich HH (1985): Wirkstoffe in der dermatologischen Therapie, 2. Aufl Springer-Verlag, Berlin, Heidelberg, New York, Tokyo, pp 133–136 und 211–213.
Roberts DT, Taylor WD, Boyle J (2003): Guidelines for treatment of onychomycosis. Br J Dermatol 148:402–410.
Sigurgeirsson B, Olafsson JH, Steinsson JB, Paul C, Billstein S, Evans EGV (2002): Long-term effectiveness of treatment with terbinafine vs itraconazole in onychomycosis. Arch Dermatol 138:353–357.
Silingardi M, Ghirarduzzi A, Tincani E, Iorio A, Iori I (2000): Miconazole oral gel potentiates warfarin anticoagulant activity. Thromb Haemost 83: 794–795.
Simon C, Stille W (2000): Antibiotika-Therapie in Klinik und Praxis, 10. Auflage. Schattauer, Stuttgart-New York, S. 330–336.
Steigleder GK (1993): Therapie der Hautkrankheiten, 4. Aufl. Georg Thieme Verlag, Stuttgart, New York.
Thirion DJ, Zanetti LA (2000): Potentiation of warfarin’s hypoprothrombinemic effect with miconazole vaginal suppositories. Pharmacotherapy 20:98–99.
Venkatakrishnan K, von Moltke LL, Greenblatt DJ (2000): Effects of the antifungal agents on oxidative drug metabolism. Clin Pharmacokinet 38:111–180.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2004 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Fricke, U. (2004). Antimykotika. In: Schwabe, U., Paffrath, D. (eds) Arzneiverordnungs-Report 2004. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-18513-7_17
Download citation
DOI: https://doi.org/10.1007/978-3-642-18513-7_17
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-21359-8
Online ISBN: 978-3-642-18513-7
eBook Packages: Springer Book Archive